Cost-Effectiveness in Health and Medicine
Peter J. Neumann, Gillian D. Sanders, Louise B. Russell, Joanna E. Siegel, Theodore G. Ganiats
Oxford University Press, Oct 3, 2016 - Medical - 496 pages
A COMPLETE UPDATE AND REVISION OF THE CLASSIC TEXT "At last, a manual of operations for comparing the cost-effectiveness of a preventive service with a treatment intervention." --American Journal of Preventive Medicine Twenty years after the first edition of COST-EFFECTIVENESS IN HEALTH AND MEDICINE established the practical benchmark for cost-effectiveness analysis, this completely revised edition of the classic text provides an essential resource to a new generation of practitioners, students, researchers, and policymakers. Produced by the Second Panel on Cost-Effectiveness in Health and Medicine--a team of 13 experts from fields including decision science, economics, ethics, psychology, and medicine--this new edition is a comprehensive guide to the use of cost-effectiveness analysis as an evaluative tool at the institutional and policy levels. As health care systems face increasing pressure to derive maximum value from expenditures, the guidelines in this new text represent not just the best information available, but a vital guide to health care decision-making in a challenging new era. Completely revised and enriched with examples and expanded coverage, this second edition of COST-EFFECTIVENESS IN HEALTH AND MEDICINE builds on its predecessor's excellence, offering required reading for both analysts and decision makers.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Recommendations on Perspectives for the Reference Case
Anirban Basu and Theodore G Ganiats
Reflecting Uncertainty in CostEffectiveness Analysis
Other editions - View all
acamprosate allocation alternative approach assumptions bias breast cancer budget cancer caregivers CEA model Chapter choice Claxton clinical colorectal cancer compared consequences consider constraints consumption context cost costeffectiveness analysis costeffectiveness ratio costeffectiveness threshold costs and effects Decis decision makers decisionmaking disease drug economic evaluation estimates ethical evidence synthesis example expected utility theory expected value framework guidelines Health and Medicine health benefits Health Econ health interventions health outcomes healthcare sector perspective healthrelated quality ICER identified Impact Inventory important incremental individuals M. C. Weinstein maximize measure Medicare metaanalysis methods naltrexone Neumann opportunity costs options original Panel palliative care patients Pharmacoeconomics population potential preferencebased priority QALYs qualityadjusted Reference Case analyses reflect relevant screening Sculpher Second Panel sensitivity analysis societal perspective specific standard gamble strategy systematic review tradeoff treatment trial vaccination valuation Value Health welfare economics